Articles related to Endocrinology, Diabetes, Metabolism

A network meta-analysis of 24 trials (16,371 patients) found complete revascularization in myocardial infarction with multivessel disease reduced all-cause mortality by 15% compared to culprit-only revascularization, suggesting potential improved outcomes for this population.

Lymphedema and lipedema, while superficially similar, have distinct pathophysiologies and management strategies. Understanding these differences is essential for providing targeted care and improving patient outcomes.

SGLT-2 inhibitors offer benefits beyond glucose control, potentially addressing the systemic inflammatory components of metabolic diseases like diabetes, heart failure, and gout.

Patients taking semaglutide for diabetes were more than four times more likely to develop NAION compared to those on other diabetes medications, while those using it for obesity had a seven-fold increased risk.

Rapid weight loss from semaglutide use can lead to breast ptosis, mirroring effects seen after bariatric surgery. Healthcare providers should be prepared to counsel patients on this potential outcome and offer strategies for management.

Careful management with endocrinology expertise is crucial when considering radioligand therapy for pheochromocytomas and paragangliomas to avoid potentially life-threatening catecholamine crises.